



**IMMUNOTHERAPY** <sup>10</sup> YEARS **2024**  
**BRIDGE**


**Naples (Italy)**  
**December 4<sup>th</sup>-5<sup>th</sup>, 2024**  
**Royal Continental Hotel**

# GENERAL INFORMATION

## CONGRESS VENUE

### Royal Continental Hotel

Via Partenope, 38 - 80121 Naples



INTERNATIONAL AIRPORT

RAILWAY STATION

CONGRESS VENUE

## REGISTRATION

Registration fee: €800.00 + 22% VAT

For information, registration, and payments, please contact:

[registration@melanomabridge.org](mailto:registration@melanomabridge.org)

Confirmation of registration will be sent by the organizing secretariat.

Only registered participants will be admitted to the event.

- » The registration fee includes:
- Participation in scientific sessions
  - Congress kit (badge, notepad, pen)
  - Coffee breaks and lunches

## OFFICIAL LANGUAGE

The official language is English.

# SCIENTIFIC RATIONAL

Over the last years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies, the Immunotherapy beyond T cells and also the novel platforms and approaches for immune monitoring will be exhaustively discussed.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

# SCIENTIFIC PROGRAM

## DAY 1 Wednesday, Dec 4<sup>th</sup>

10.00 am Introduction and Objectives  
**Paolo A. Ascierto**

### SITvC SESSION

#### TIL ADVANCEMENTS: CAR-T AND TILS

Chairpersons: **Leisha A Emens, Stephanie L. Goff**

10.10 am Overview on Cell Therapy and Enhancements for CAR T-cell activity  
**Avery D. Posey**

10.25 am Q&A

10.30 am Novel technologies to enhance immune cells functions  
**Timothy Lu**

10.45 am Q&A

10.50 am CAR-T Therapy  
**Renier Brentjens**

11.05 am Q&A

11.10 am TIL for melanoma: the time is now  
**Stephanie L. Goff**

11.25 am Q&A

11.30 am The best of SITC 2024  
**Paolo A. Ascierto**

11.45 am Q&A

12.00 pm **LECTURE**  
The Evolutionary Landscape of Gastrointestinal Treatment  
**Antonio Avallone**  
Immunotherapy in treatment of endometrial cancer  
**Domenica Lorusso**

12.30 pm **Lunch\*\***

*\*Invited Speakers*

*\*\* Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

## DAY 1 Wednesday, Dec 4<sup>th</sup>

### GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov**

- 1.30 pm Should we continue to add something to checkpoint inhibitors or we need to change strategy?  
**Hussein Tawbi vs Omid Hamid**
- 1.55 pm Should we do combination immunotherapy trials with drugs that lack single agent activity? Yes or no  
**Bernard A. Fox vs Igor Puzanov**
- 2.20 pm ADCs VS Bispecific  
**Leisha A. Emens vs Samir Khleif**

### SESSION 2

**IMMUNOTHERAPY BEYOND T CELLS AND IMMUNOTHERAPY BEYOND CLASSICAL T CELLS**

Chairpersons: **Alfredo Budillon, Luigi Buonaguro**

- 2.45 pm B cells  
**Chrystal M. Paulos**
- 3.00 pm NK Cell  
**Timothy Lu**
- 3.15 pm Myeloid Cells  
**Jennifer Guerriero**
- 3.30 pm Neutrophil Cells  
**Brahm Segal**
- 3.45 pm Macrophages as tools and targets in cancer therapy  
**Cecilia Garlanda**
- 4.00 pm Armored CAR-T Cells  
**Renier Brentjens**
- 4.15 pm **DISCUSSION Round Table**

*\*Invited Speakers*

*\*\* Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

## DAY 1 Wednesday, Dec 4<sup>th</sup>

### SESSION 3

#### IMMUNE MONITORING: NOVEL PLATFORMS AND APPROACHES

Chairpersons: **Elizabeth M. Burton**, **Lisa H. Butterfield**

- 4.45 pm Landscape/overview of trends in biomarker proposals - CIMAC/SITC  
**Holden Terry Maecker**
- 5.00 pm Integrating data across biomarker platforms  
**Christine N. Spencer**
- 5.10 pm Leveraging AI to integrate image based analyses  
**Lacey Padron**
- 5.30 pm **DISCUSSION Round Table**

*\*Invited Speakers*

*\*\* Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

## DAY 2 Thursday, Dec 5<sup>th</sup>

### SESSION 4

#### ORGAN SPECIFIC IMMUNE RESPONSE

Chairpersons: **Omid Hamid, Sandro Pignata**

- 9.30 am Pancreatic Cancer  
**Renato Ostuni**
- 9.40 am Lung cancer  
**Alessandro Morabito**
- 9.50 am Renal cancer  
**Tony Choueiri**
- 10.00 am GU cancer  
**Akash Patnaik**
- 10.10 am GI cancer  
**Gregory B. Lesinski**
- 10.20 am Endometrial Cancer  
**Emese Zsiros**
- 10.30 am Ovarian Cancer  
**Kunle Odunsi**
- 10.40 am Head & Neck  
**Robert L. Ferris**
- 10.50 am **DISCUSSION Round Table**

### 11.20 pm SYMPOSIUM

Therapeutic strategies in advanced RCC: focus on patient for the treatment choice

**Sarah Scagliarini**

Frontiers in Thoracic Oncology: transforming Early-Syage Care and Targeted Therapies for Improved Patient Outcomes

**Alessandro Morabito**

Immunotherapy in GI tumors: what we have learned

**Claudia Lotesorriere\***

*\*Invited Speakers*

*\*\* Not included in the CME accredited program*

# SCIENTIFIC PROGRAM

## DAY 2 Thursday, Dec 5<sup>th</sup>

### GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, Igor Puzanov**

12.10 am No role for first chemo-immuno VS vegf/immuno first line  
**Robert L. Ferris vs Toni Choueiri**

12.35 pm Pre-treatment predictive biomarkers: INF g vs. Immunoscore vs. multiplex  
IF/next-generation spatial biology  
**Christian Blank vs Jerome Galon vs Janis Taube**

1.10 pm Do we need vaccines? Yes or no  
**Pawel Kalinski vs Stephen Schoenberger**

1.35 pm **Lunch\*\***

### 2.30 pm SYMPOSIUM

Non-Melanoma Skin Cancers

**Paolo A. Ascierto, Dirk Schadendorf**

### SESSION 5

#### NEOADJUVANT THERAPY ACROSS CANCERS

Chairpersons: **Paolo A. Ascierto, Elizabeth M. Burton**

3.20 pm INNOVATE summary  
**Paolo A. Ascierto**

3.35 pm Breast  
**Leisha A. Emens**

3.50 pm Lung  
**Tina Cascone**

4.05 pm Melanoma  
**Christian Blank**

4.20 pm Non Melanoma Skin Cancers  
**Neil Gross**

4.35 pm Translational insights from anti-LAG3  
**Elizabeth M. Burton**

4.50 pm Pan tumor path response assessment  
**Julie Stein Deutsch**

5.05 pm **DISCUSSION Round Table**

5.30 pm **Conclusion**

*\*Invited Speakers*

*\*\* Not included in the CME accredited program*



# PRESIDENCY



## **Paolo A. Ascierto**

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy



## **Leisha A. Emens**

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; President of Society for Immunotherapy of Cancer (SITC)



## **Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US



## **Igor Puzanov**

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

# SCIENTIFIC BOARD

## **Sanjiv S. Agarwala**

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

## **Paolo A. Ascierto**

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy

## **Carlo Bifulco**

Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

## **Christian Blank**

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

# SCIENTIFIC BOARD

## **Elizabeth M. Burton**

Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

## **Lisa H. Butterfield**

Adjunct Professor of Microbiology and Immunology, University of California San Francisco, CA, US

## **Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

## **Mary Dean**

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

## **Sandra Demaria**

Professor of Radiation Oncology, Professor of Pathology and Laboratory Medicine Weill Cornell Medicine, New York, NY, US

## **Reinhard Dummer**

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

## **Alexander M.M. Eggermont**

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, Netherlands

## **Leisha A. Emens**

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; President of Society for Immunotherapy of Cancer (SITC)

## **Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

## **Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

## **Jeffrey E. Gershenwald**

Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA

## **Omid Hamid**

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

# SCIENTIFIC BOARD

## **Samir N. Khleif**

Director of Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US

## **Giuseppe Masucci**

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

## **Olivier Michielin**

Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora - Lausanne, Switzerland

## **Iman Osman**

Rudolf Baer Professor of Dermatology Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US

## **Giuseppe Palmieri**

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

## **Michael A. Postow**

Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

## **Igor Puzanov**

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

## **Dirk Schadendorf**

Director of the Department of Dermatology, University Hospital Essen, Essen, Germany

## **Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

## **Tara Withington**

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

# CONTINUING MEDICAL EDUCATION

## CME Provider

T&C srl - Provider No. 13  
Via Giotto 3, 20145 Milan, Italy  
E-mail: raffaella.ottoboni@tccompany.it

## CME Credits

CME Code: 13 - 431595 Ed.1

The course has been accredited with 3.9 CME credits.

The regulations for the acquisition of CME credits are available on the website:  
[www.tccompany.it](http://www.tccompany.it).

To obtain CME credits, participants must attend at least 90% of the total course duration and complete the event evaluation.

## National Objective:

Technical and professional content (knowledge and skills) specific to each profession, specialization, and ultra specialized activity, including rare diseases and gender medicine.

## Target Audience:

This course is intended at 250 participants among the following professions:

- Pharmacists
- Biologists
- Medical Doctors specializing in:  
Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Gastroenterology, Respiratory diseases, Internal Medicine, Nephrology, Neurology, Oncology, Radiotherapy, General Surgery, Plastic and Reconstructive Surgery, Gynecology and Obstetrics, Urology, Pathological Anatomy, Clinical Pharmacology and Toxicology, Medical Genetics Laboratory, Nuclear Medicine, Clinical Pathology (Chemical-Clinical Laboratory and Microbiology), Radio diagnostics, Hygiene, Epidemiology, and Public Health, General Medicine (General Practitioners), Nutrition Science and Dietetics, Palliative Care
- Pediatric Nurses
- Nurses

### **CME PROVIDER**

#### **T&C Srl**

Via Giotto 3, 20145 Milan, Italy

Cell. 334/1837054

[www.tccompany.it](http://www.tccompany.it)



### **ORGANIZING SECRETARIAT**

#### **Vivenko Srl Società Benefit**

Via De Amicis 42, 20123 Milan, Italy

[www.vivenko.net](http://www.vivenko.net)

[info@melanomabridge.org](mailto:info@melanomabridge.org)

